Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
ICU Medical's Sloan Ratio for the quarter that ended in Jun. 2026 was -3.15%.
As of Jun. 2026, ICU Medical has a Sloan Ratio of -3.15%, indicating the company is in the safe zone and there is no funny business with accruals.
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, ICU Medical has a Sloan Ratio of -3.15%, indicating the company is in the safe zone and there is no funny business with accruals.
ICU Medical Sloan Ratio % Related Terms
ICU Medical Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for ICU Medical's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IC7 vs NVST, MMSI, MMED: Sloan Ratio % Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where ICU Medical's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
ICU Medical's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
ICU Medical's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was -2.893 (Sep. 2025 ) + -13.437 (Dec. 2025 ) + 26.064 (Mar. 2026 ) + 16.568 (Jun. 2026 ) = €26 Mil.
ICU Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 48.317 (Sep. 2025 ) + 51.752 (Dec. 2025 ) + 33.656 (Mar. 2026 ) + 69.57 (Jun. 2026 ) = €203 Mil.
ICU Medical's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -25.584 (Sep. 2025 ) + -15.706 (Dec. 2025 ) + -9.696 (Mar. 2026 ) + -17.479 (Jun. 2026 ) = €-68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (FRA:IC7) has a Sloan Ratio % of -3.15% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on ICU Medical and its competitors.
Is ICU Medical's Sloan Ratio % too high?
ICU Medical's current Sloan Ratio % is -3.15%. Overall, ICU Medical has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Sloan Ratio % compare to NVST and MMSI?
ICU Medical's Sloan Ratio % of -3.15% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on ICU Medical and its competitors. ICU Medical's current Sloan Ratio % is -3.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (FRA:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €103.53, compared to a current price of €157.00 — trading 51.6% above its estimated fair value. The current Sloan Ratio % is -3.15%. ICU Medical's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For ICU Medical (FRA:IC7), the current Sloan Ratio % is -3.15% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (FRA:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €157.00 is trading 51.6% above its estimated GF Value™ of €103.53.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for FRA:IC7:
Sloan Ratio %: -3.15%
GF Value™: €103.53 vs. price of €157.00 (51.6% above fair value)
No single metric tells the full story. See the FRA:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
78GF Score
Get the complete analysis for FRA:IC7
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IC7 has been successfully added to your 
